CSL slides amid US vax policy

The global biotech dropped its CEO and saw its share price plummet after flagging a fall in profit, competition in iron generics and the impact of US vaccine policy Melbourne-based market darling CSL had a bad day on the stock exchange after its CEO was retired and it noted changes in the “highly dynamic” US